Pre-diagnostic anti-EBV antibodies and primary liver cancer risk: a population-based nested case-control study in southern China

被引：1

作者：

Du, Yun ^{[1
,2
]}

Yu, Xia ^{[1
]}

Chang, Ellen T. ^{[3
]}

Lian, Shifeng ^{[4
]}

Wu, Biaohua ^{[1
]}

Li, Fugui ^{[1
]}

Chu, Bing ^{[5
]}

Wei, Kuangrong ^{[1
]}

Zhan, Jiyun ^{[6
]}

Liang, Xuejun ^{[6
]}

Ye, Weimin ^{[2
]}

Ji, Mingfang ^{[1
]}

机构：

[1] Zhongshan City Peoples Hosp, Canc Res Inst Zhongshan City, Zhongshan 528400, Peoples R China

[2] Karolinska Inst, Dept Med Epidemiol & Biostat, S-17177 Stockholm, Sweden

[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA

[4] Karolinska Inst, Inst Environm Med, Unit Integrat Epidemiol, S-17177 Stockholm, Sweden

[5] Zhongshan City Peoples Hosp, Dept Pathol, Zhongshan 528400, Peoples R China

[6] Xiaolan Publ Hlth Serv Ctr, Zhongshan 528400, Peoples R China

来源：

BMC CANCER | 2023年 / 23卷 / 01期

基金：

中国国家自然科学基金;

关键词：

Primary liver cancer; Epstein-Barr virus; Antibody; Nested case-control study; Population-based; Epidemiology; EPSTEIN-BARR-VIRUS; HEPATOCELLULAR-CARCINOMA; HEPATITIS-B; DNA; EPIDEMIOLOGY; INFECTION; RNA;

D O I：

10.1186/s12885-023-10709-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundWe aimed to investigate associations between pre-diagnostic anti-Epstein-Barr virus (EBV) antibodies, including interactions with hepatitis B virus (HBV), and risk of primary liver cancer in southern China.MethodsIn a population-based nested case-control study, we measured pre-diagnostic immunoglobulin A (IgA) against EBV nuclear antigen 1 (EBNA1) and viral capsid antigen (VCA) in 125 primary liver cancer cases and 2077 matched controls. We also explored the interaction between HBV surface antigen (HBsAg) and anti-EBV antibodies.ResultsParticipants with positive EBNA1-IgA, positive VCA-IgA or single-positive anti-EBV antibodies had two-fold odds of developing liver cancer, compared with seronegative subjects. The odds ratios (ORs) between the relative optical density of EBNA1-IgA and VCA-IgA and primary cancer, controlling for age and HBsAg, were 1.59 (95% confidence interval (CI): 1.17, 2.14) and 1.60 (95% CI: 1.07, 2.41), respectively. Subjects with both HBsAg and anti-EBV antibody seropositivity were at 50-fold increased risk compared with those negative for both biomarkers (OR: 50.67, 95% CI: 18.28, 140.46), yielding a relative excess risk due to interaction of 30.81 (95% CI: 3.42, 114.93).ConclusionPre-diagnostic seropositivity for EBNA1-IgA and/or VCA-IgA was positively associated with primary liver cancer risk, especially in combination with HBsAg positivity. EBV may interact with HBV in the development of primary liver cancer, and anti-EBV antibodies might be potential biomarkers for primary liver cancer in this high-risk population.

引用

页数：9